

Grifols appoints Miguel Louzan Chief Digital Information Officer

- *In his newly created role, Mr. Louzan will drive the company's digital transformation and information technology priorities, ensuring the companywide integration of advanced capabilities to help accelerate business growth and lead cybersecurity*
- *Mr. Louzan is an international pharmaceutical information technology executive with nearly 30 years of experience leading digital and data transformation*

Barcelona, Spain, Sept. 19, 2023 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma medicines with more than 110 years contributing to improve the health and well-being of people, today announced that it has named Miguel Louzan Chief Digital Information Officer (CDIO).

Mr. Louzan is Grifols' first CDIO, a responsibility that recognizes the convergence of digital technologies and the broader category of information systems. His mandate is to accelerate the company's use of digital platforms, data science and new technologies to transform and strengthen critical business activities such as relationships with plasma donors and customers as well as manufacturing operations, the development of new therapeutics and cybersecurity. Accordingly Mr. Louzan will focus on greater application of artificial intelligence, point-of-contact technologies and other automation tools that will help Grifols drive its strategic growth plans effectively and efficiently.

He will also look to add to the world-class partnerships Grifols is leveraging as part of its ongoing efforts to make technology a differentiating company attribute. Most recently, Grifols forged a collaboration with Google Cloud to speed up the development of new therapeutics in its flagship Biopharma business unit.

A veteran of the global pharmaceutical and healthcare industries, Mr. Louzan has almost 30 years' experience building and executing world-class digital and data transformation initiatives for drug and medical device companies and manufacturers.

Before Grifols, Mr. Louzan was managing director for technology transformation at a major private equity firm, where he advised leading companies on their digital and technology strategies. Before this he was the chief information officer for LifeScan, a company specializing in diabetes care. Mr. Louzan also held senior IT management positions with UCB Pharma, dedicated to treating neurological and immunological diseases, and Boston Scientific, a maker of medical devices. He was also chief information officer for SWM, a manufacturer of paper and fiber as well as resin products.

"Miguel has the experience and track record to make Grifols a clear leader in our application of digital and new technologies to help drive efficient growth and support our mission of enhancing the health and well-being of people," said Victor Grifols Deu, Grifols Chief Operating Officer.

“I’m thrilled to join a globally revered healthcare leader such as Grifols, where there are great opportunities to upscale the company’s digital and technology platforms to create value for the entire organization and its stakeholders,” said Mr. Louzan.

Mr. Louzan holds a bachelor’s degree in accounting and finance from Cooremans University, in Brussels, and an MBA from Emory University’s Goizueta Business School.

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Tel. +34 93 571 00 02

Spain

Duomo Comunicación

Tel.: +34 91 311 92 89 – 91 311 92 90

Raquel Lumbreras

raquel_lumbreras@duomocomunicacion.com

Tel.: +34 659 57 21 85

Borja Gómez

borja_gomez@duomocomunicacion.com

Tel.: 650 40 22 25

Investor contact:

Investor Relations

inversores@grifols.com - investors@grifols.com

Tel.: +34 93 571 02 21

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and our ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world’s largest with over 390 across North America, Europe, Africa and the Middle East and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. We provide high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

In 2022, Grifols' economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit [grifols.com](https://www.grifols.com)

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.